November 21, 2024
Suitable preclinical models such as patient-derived xenografts (PDX) are needed to evaluate drugs specifically targeting adrenal gland cancer. PDX models are known to be the most predictive preclinical model and provide the most accurate approach to evaluating an agents efficacy prior to entering the clinic. The Crown Bioscience adrenal gland PDX collection consists of several models, including models from both North American and Asian descent. More
PDX offer the most translational preclinical model for efficacy screening in cancer drug development. Derived directly from patient tumors and never adapted to grow in vitro, PDX models reflect the heterogeneity and diversity of the human patient population. PDX give you an accurate, predictive model of how your treatment will perform, well before entering into expensive clinical trials. Crown Bioscience's HuPrime® PDX models are well characterized for pathology, growth characteristics, and are also genetically/genomically annotated for gene expression, gene copy number, mutations, and fusions.
MODEL NUMBER | CANCER TYPE | CANCER SUBTYPE | DESCRIPTION | # per page |
---|---|---|---|---|
AD0344 | Adrenal Gland Cancer | NA | Small cell carcinoma of left adrenal gland, infiltrating into soft tissue of left kidney. No malignant cell adjacent to urethral stump. IHC results: Syn(+), Chr-A(+), CK(+), NSE(+), Vim(-). | CLICK TO VIEW |
AD0484 | Adrenal Gland Cancer | NA | NA for clinical diagnosis info. | CLICK TO VIEW |
AD10272 | Adrenal Gland Cancer | NA | Adrenal cortical carcinoma | CLICK TO VIEW |
Already Registered? Login
© 2024 Crown Bioscience. All Rights Reserved.
© 2024 Crown Bioscience. All Rights Reserved. Privacy Policy